Promoted Content
Promoted Content

Find Novel Dermatology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HT-003

            Therapeutic Area: Dermatology Product Name: HT-003

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hoth Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration January 28, 2021

            Details:

            The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HT-001

            Therapeutic Area: Dermatology Product Name: HT-001

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Charles River Laboratories, Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 11, 2021

            Details:

            Hoth Therapeutics has entered into an agreement with Charles River Laboratories to start preclinical studies of HT-001, a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 08, 2021

            Details:

            Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Evommune

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 07, 2021

            Details:

            Agreement aims to develop and commercialize three development programs for the treatment of various inflammatory diseases which include IRAK4/TrkA; RORγt; and MRGPRX2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HT-001

            Therapeutic Area: Dermatology Product Name: HT-001

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 23, 2020

            Details:

            HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy, as there are currently no approved drugs to specifically treat EGFR inhibitor-induced skin disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAN10

            Therapeutic Area: Dermatology Product Name: CAN10

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cantargia AB

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 26, 2020

            Details:

            CAN10 is fully humanized monoclonal antibody targeting IL1RAP. BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.

            Weill Cornell Medicine

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 16, 2020

            Details:

            Dr. Richard Granstein, M.D., Chairman of Dermatology at Weill Cornell Medicine in New York City, will initiate an investigator-led clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JT-09

            Therapeutic Area: Dermatology Product Name: JT-09

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Titan Pharmaceuticals Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering November 02, 2020

            Details:

            As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline and JT-09.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATR-01

            Therapeutic Area: Dermatology Product Name: ATR-01

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Leaps by Bayer

            Deal Size: $17.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing October 15, 2020

            Details:

            The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products and consumer programs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            Derm-Biome's topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. The drug showed comparable inhibitory effects to tapinarof over a similar range of concentrations.

            PharmaCompass